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Clinical and Genetic Association of Serum Ceruloplasmin
With Cardiovascular Risk
W.H. Wilson Tang, Yuping Wu, Jaana Hartiala, Yiying Fan, Alexandre F.R. Stewart, Robert Roberts,
Ruth McPherson, Paul L. Fox, Hooman Allayee, Stanley L. Hazen
Objective—Ceruloplasmin (Cp) is an acute-phase reactant that is increased in inflammatory diseases and in acute coronary
syndromes. Cp has recently been shown to possess nitric oxide (NO) oxidase catalytic activity, but its impact on
long-term cardiovascular outcomes in stable cardiac patients has not been explored.
Methods and Results—We examined serum Cp levels and their relationship with incident major adverse cardiovascular
events (MACE; death, myocardial infarction [MI], stroke) over 3-year follow-up in 4177 patients undergoing elective
coronary angiography. We also carried out a genome-wide association study to identify the genetic determinants of
serum Cp levels and evaluate their relationship to prevalent and incident cardiovascular risk. In our cohort (age 6311
years, 66% male, 32% history of MI, 31% diabetes mellitus), mean Cp level was 246 mg/dL. Serum Cp level was
associated with greater risk of MI at 3 years (hazard ratio [quartile 4 versus 1] 2.35, 95% confidence interval [CI]
1.79–3.09, P0.001). After adjustment for traditional risk factors, high-sensitivity C-reactive protein, and creatinine
clearance, Cp remained independently predictive of MACE (hazard ratio 1.55, 95% CI 1.10–2.17, P0.012). A 2-stage
genome-wide association study identified a locus on chromosome 3 over the CP gene that was significantly associated
with Cp levels (lead single-nucleotide polymorphism rs13072552; P1.901011). However, this variant, which leads
to modestly increased serum Cp levels (1.5–2 mg/dL per minor allele copy), was not associated with coronary artery
disease or future risk of MACE.
Conclusion—In stable cardiac patients, serum Cp provides independent risk prediction of long-term adverse cardiac
events. Genetic variants at the CP locus that modestly affect serum Cp levels are not associated with prevalent or
incident risk of coronary artery disease in this study population.
Ceruloplasmin (Cp) is a circulating ferroxidase enzymeable to oxidize ferrous ions to less toxic ferric forms.1 It
is the major carrier of circulating copper and is synthesized
and secreted by the liver. Cp not only acts as a mediator of
iron oxidation but also is an acute phase reactant in the setting
of inflammation (such as infections or inflammatory arthri-
tis). In contrast, inherited liver disorders such as Wilson
disease may present with lower than normal levels of circu-
lating Cp.
Recent studies support a role of Cp in regulating nitric
oxide (NO) homeostasis.2 Isolated Cp was shown capable of
catalytically consuming NO through NO oxidase activity, and
plasma NO oxidase activity was decreased after Cp immu-
nodepletion, in Cp knockout mice, and in people with
congenital aceruloplasminemia.2 A mechanistic role for Cp in
vascular disease beyond its association as an acute phase
protein is thus suggested. Interestingly, myocardial uptake of
Cp has been demonstrated in animal models,3 and epidemi-
ological studies have linked Cp levels with cardiovascular
risk both in apparently healthy individuals4–7 and in the
setting of acute coronary syndromes.8–10 Despite the relative
ease and affordability of Cp testing, few studies have exam-
ined Cp and its association with cardiovascular outcomes.
The clinical prognostic value of Cp levels is not well




The Cleveland Clinic GeneBank study is a large, prospective cohort
study, run from 2001 to 2006, that established a well-characterized
clinical repository with clinical and longitudinal outcomes data
composed of consenting subjects undergoing elective diagnostic
cardiac catheterization procedure. All GeneBank participants gave
written informed consent approved by the Cleveland Clinic Institu-
tional Review Board. This analysis included 4177 consecutive
subjects of white European ancestry without evidence of myocardial
infarction (MI; cardiac troponin I 0.03 ng/mL) with plasma
samples available for analysis. An estimate of creatinine clearance
was calculated using the Cockcroft-Gault equation. The presence of
coronary artery disease (CAD) was confirmed by luminal stenosis of
at least 50% in any major coronary arteries. Major adverse cardio-
vascular event (MACE) was defined as death, nonfatal MI, or
nonfatal cerebrovascular accident following enrollment. Adjudicated
outcomes were ascertained over the ensuing 3 years for all subjects
following enrollment.
Cp Assay
Quantitative determination of Cp was performed using an immuno-
turbidimetric assay (Architect ci8200, Abbott, Abbott Park IL),
which provides highly sensitive measurement of Cp levels with an
intraassay coefficient of variation of 3.7%, interassay precision of up
to 4%, and a reference range of 20 to 60 mg/dL. High-sensitivity
C-reactive protein (hsCRP), myeloperoxidase (MPO), uric acid,
creatinine, and fasting blood glucose and lipid profiles were mea-
sured on the same platform, as previously described.11
Genotyping
Genome-wide genotyping of single-nucleotide polymorphisms
(SNPs) was performed on the Affymetrix Genome-Wide Human
Array 6.0 chip in a subset of European ancestry patients in Gen-
eBank. Using these data and those from 120 phased chromosomes
from the HapMap CEU samples (HapMap r22 release, National
Center for Biotechnology Information build 36), genotypes were
imputed for untyped SNPs across the genome using MACH 1.0
software. All imputations were done on the forward () strand using
562 554 genotyped SNPs that had passed quality control filters.
Quality control filters for the imputed data set excluded SNPs with
Hardy-Weinberg equilibrium probability values 0.0001 or minor
allele frequencies 1%, and individuals with less than 95% call
rates. This resulted in 2 421 770 autosomal SNPs that were available
for analysis.
Statistical Analyses
The Student t test or Wilcoxon-Rank sum test for continuous
variables and 2 test for categorical variables were used to examine
the difference between the groups. Kaplan-Meier analysis with Cox
proportional hazards regression was used for time-to-event analysis
to determine hazard ratio and 95% confidence intervals (95% CI) for
1-year and 3-year MACE. Levels of Cp were then adjusted for
traditional cardiac risk factors in a multivariable model, including
age, gender, diabetes mellitus, systolic blood pressure, low- and
high-density lipoprotein, and triglyceride, as well as log-transformed
hsCRP and creatinine clearance. Receiver operating characteristic
curve analyses and 5-fold cross validation were used to determine the
optimal cutoff. The improvement in model performance introduced
by the inclusion of Cp was evaluated using net reclassification
improvement index. The C statistic was calculated using the area
under the receiver operating characteristic curve. To determine the
optimal cutoff for Cp, we used a logistic regression model to
estimate the risk of MACE. The 5-fold cross validation divides the
data into 5 approximately equally sized portions, and a logistic
regression model is trained on 4 parts of the data and then estimates
the risk of MACE in the fifth part. This is repeated for each of the 5
parts, and the area under the curve with the estimated risk was
calculated. This process is carried out for a grid of values of Cp
cutoff values, ranging from 17.3 mg/dL (10th percentile) to 31.5
mg/dL (90th percentile) with an increment of 0.1 mg/dL. The
optimal cutoff is chosen to maximize area under the curve values.
Probability values 0.05 were considered statistically significant.
A genome-wide association study (GWAS) for serum Cp levels
was carried out with adjustment for age and gender under an additive
model. Linear regression analyses were carried out with PLINK
(version 1.07) using log-transformed values. Unconditional multiple
logistic regression was used to independently test for association of
genetic variants with the presence and severity of CAD, with
adjustment for age, gender, medication use (aspirin or statins), and
Framingham Adult Treatment Panel III risk score (which includes
smoking and diabetes status). Relative risk for experiencing a MACE
was assessed using Cox proportional hazard models with adjustment
for age, gender, medication use, and Framingham Adult Treatment
Panel III risk score. These analyses were carried out assuming
additive and dominant models. Adjusted odds or hazard ratios (OR
or hazard ratio) with 95% CIs are reported with 2-sided probability
values. All statistical analyses were performed using R version 9.2
(R Foundation for Statistical Computing, Vienna, Austria) and SAS
version 9.2 (SAS Institute Inc, Cary, NC).
Results
Baseline characteristics of the study population are shown in
Table 1. The mean and median serum Cp levels were 24 and
23 mg/dL (interquartile range 20–27 mg/dL), respectively.
Patients with elevated Cp were more likely to be older and
female, with more cardiovascular risk factors, including
dyslipidemia, history of diabetes mellitus, and poorer renal
function at baseline. There was strong direct correlation
between Cp and hsCRP (r0.52, P0.001) but far weaker
correlations with total leukocyte count (r0.15, P0.001) or
Table 1. Baseline Characteristics
Without Event With Event
Demographics and cardiovascular
risk factors
Age, y 6311 6710
Male, % 67 64
Diabetes mellitus, % 29 41
Hypertension, % 70 75
Smokers, former/current, % 65 70
Prior myocardial infarction, % 31 44
Laboratory data
LDL cholesterol, mg/dL 95 (77–116) 95 (77–116)
HDL cholesterol, mg/dL 34 (28–41) 33 (27–40)
Triglycerides, mg/dL 114 (83–162) 120 (84–163)
Total leukocyte count, 109 cells/L 6.04 (5.02–7.34) 6.21 (5.07–7.53)
Uric acid, mg/dL 6.1 (5.1–7.2) 6.5 (5.5–7.8)
hsCRP, mg/L 1.95 (0.90–4.36) 3.50 (1.46–7.22)
Myeloperoxidase, pg/mL 102 (70–189) 115 (74–227)
Creatinine clearance,
mL/min1.73 m2
102 (79–127) 86 (59–114)
Baseline medications
Aspirin, % 74 67




Statin therapy, % 60 55
Events are defined as death, myocardial infarction, or stroke. Values are
expressed as median (interquartile ranges). LDL indicates low-density lipopro-
tein; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein.
MPO (r0.12, P0.001) and no correlation with serum uric
acid levels (r0.02, P0.09).
Association of Serum Cp Levels With
Future MACE
Table 2 demonstrates the relationship between Cp levels in
quartiles with 3-year risk for incident MACE. This graded
risk was clearly illustrated in the Kaplan-Meier analysis
(Figure 1A) when stratified according to quartile Cp ranges
(quartiles 1 versus 4, hazard ratio: 2.35, 95% CI 1.79–3.09,
P0.001). After adjustment for traditional risk factors, in-
creased Cp levels remained significantly associated with
incident major long-term major adverse cardiac events at 3
years (Table 2). The results were similar when stratified by
gender, even though the cutoffs of the quartiles were higher in
women (adjusted hazard ratio 1.77, 95% CI 1.13–2.77,
P0.013; fourth quartile Cp 31.5 mg/dL) than in men
(adjusted hazard ratio 2.55, 95% CI 1.82–3.57, P0.001;
fourth quartile Cp 24.6 mg/dL). In particular, those with
elevated Cp (cutoff at 22 mg/dL) and MPO (cutoff at 322
pg/mL), another known oxidase that contributes to catalytic
consumption of NO within the vascular compartment,12–14
experienced the highest risk of developing future MACE
(Figure 1B). Such prognostic value remained significant in
various subgroups stratified by age, gender, presence of
diabetes mellitus, hypertension, or renal insufficiency (Figure
2). When results were stratified by hsCRP or with MPO, we
observed synergistic prediction of future MACE (Figure 3
and Table 2). Inclusion of Cp resulted in a significant
improvement in risk estimation, based on net reclassification
improvement index (9.6%, P0.001) and C statistic (67.7%
versus 65.2%, P0.003).
GWAS for Serum Cp Levels
We next performed a 2-stage GWAS for serum Cp levels in
4697 GeneBank subjects (all of European ancestry). In stage
1 (n2647), the genomic inflation factor was 1.001, indicat-
ing that the GWAS results are not affected by underlying
population (Figure 4). Serum Cp levels were primarily
controlled by a single locus on chromosome 3, which con-
Table 2. Adjusted Hazard Ratio for Major Adverse Cardiac Events at 3-y Follow-Up
According to Serum Ceruloplasmin Quartiles
Serum Ceruloplasmin Level
Quartile 1 Quartile 2 Quartile 3 Quartile 4
All subjects (n4177)
Range, mg/dL 19.9 19.9–23.1 23.1–27.0 27.0
Event rate 74/1044 106/1044 133/1042 169/1047
Unadjusted 1 1.46 (1.09–1.97)* 1.91 (1.44–2.53)† 2.35 (1.79–3.09)†
Adjusted
Model 1 1 1.38 (1.02–1.87)* 1.66 (1.24–2.22)† 2.22 (1.64–3.00)†
Model 2 1 1.40 (1.03–1.91)* 1.82 (1.35–2.45)† 2.47 (1.81–3.39)†
Model 3 1 1.25 (0.93–1.69) 1.39 (1.03–1.88)* 1.50 (1.06–2.13)*
Secondary prevention subjects (n3100)
Event rate 60/772 93/774 109/779 143/775
Unadjusted 1 1.59 (1.16–2.2)† 1.84 (1.35–2.52)† 2.48 (1.84–3.35)†
Adjusted
Model 1 1 1.45 (1.04–2.02)* 1.54 (1.11–2.14)† 2.08 (1.48–2.91)†
Model 2 1 1.49 (1.06–2.08)* 1.67 (1.19–2.34)† 2.42 (1.70–3.43)†
Model 3 1 1.34 (0.97–1.86) 1.33 (0.95–1.87) 1.54 (1.05–2.25)*
Primary prevention subjects (n1077)
Event rate 12/269 14/269 23/268 18/271
Unadjusted 1 1.17 (0.55–2.53) 2.00 (1.00–4.00) 2.41 (1.23–4.72)*
Adjusted 1 1.35 (0.62–2.93) 2.42 (1.20–4.87)* 3.19 (1.54–6.62)†
Model 1 1 1.40 (0.64–3.05) 2.51 (1.24–5.09)* 3.54 (1.71–7.35)†
Model 2 1 1.14 (0.52–2.52) 1.77 (0.87–3.62) 1.74 (0.76–4.00)
Model 3
Model 1: adjusted for traditional risk factors (including age, gender, systolic blood pressure, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, smoking, diabetes mellitus) and medications (angiotensin coverting
enzyme inhibitors, beta-blockers, statin, aspirin). Model 2: adjusted for traditional risk factors plus myeloperoxidase.
Model 3: adjusted for traditional risk factors plus high-sensitivity C-reactive protein and serum uric acid. HR indicates
hazard ratio; MACE, major adverse cardiac events (death, myocardial infarction, stroke).
*P0.05 (compared with first quartile).
†P0.01 (compared with first quartile).
tains the CP gene itself. As shown in Table 3, the lead SNP
at this locus (rs13072552) modestly but significantly in-
creases of serum Cp levels by 2 to 3 mg/dL as a function of
carrying 1 or 2 copies of the T allele (P3.631013). The
rs13072552 SNP has a minor allele frequency of 0.08, is
located in intron 9 of CP, and is in strong linkage disequi-
librium (r20.7) with the 2 other SNPs at this locus
(rs11714000 and rs11921705) that exhibit similar association
with Cp levels (data not shown). In stage 2, we genotyped
2050 additional GeneBank subjects in whom Cp levels were
available and confirmed the association of rs13072552
(P2.42102). This association remained highly signifi-
cant in a combined analysis with all 4697 subjects (Table 3),
and an analysis stratified by gender did not suggest that the
association was gender-specific (Supplemental Table I, avail-
able online at http://atvb.ahajournals.org).
Association of CP Variants With Prevalent and
Incident Risk of CAD
We next sought to determine whether the genetic factors
controlling Cp levels were associated with prevalent and
incident risk of CAD. In addition to the 4697 subjects used
for the quantitative analyses described above, we genotyped
rs13072552 in 3448 additional GeneBank subjects with
available CAD phenotype data for these analyses (total
n8145). Under an additive model, the T allele of
rs13072552, which increases serum Cp levels, was not
associated with the presence or severity of CAD (Table 4).
We also did not observe an association with history of MI in
subjects with CAD or with future risk of MACE (Table 4) or
when males and females were analyzed separately for MACE
(P0.39 for males; P0.51 for females). Given the small
number of subjects and to increase power, we also carried out
these analyses using a dominant model with TT homozygotes
grouped together with GT heterozygotes. However, these
analyses also did not reveal an association with CAD, history
of MI, or MACE (Table 4).
Discussion
A key finding of this study is the strong independent
prognostic value of circulating Cp levels in stable patients
undergoing cardiac evaluation in the contemporary statin era,
above and beyond traditional cardiac risk factors, as well as
cardiac and inflammatory risk markers. However, the effect
of underlying genetic determinants of serum Cp levels were
modest, and there was no gender-specific difference in
prognostic value despite higher serum levels of Cp observed
in women versus in men. With the broad availability and
economic testing for serum Cp measurements in the
clinical setting, these findings highlight the need to gain
further insights into underlying pathophysiologic process
Figure 2. Forrest plot of risk prediction for serum ceruloplasmin
levels according to subgroups. DM indicates diabetes mellitus;
HTN, hypertension; CAD, coronary artery disease; hsCRP, high-
sensitivity C-reactive protein; WBC, white blood cell; MPO,
myeloperoxidase.
Figure 1. Kaplan-Meier analysis for 3-year major adverse car-
diac events stratified according to serum ceruloplasmin quartiles
(A) and for groups stratified by high/low serum ceruloplasmin
(22 mg/dL vs 22 mg/dL) and high/low plasma myeloperoxi-
dase levels (322 pg/mL vs 322 pg/mL) (B). Cp indicates
ceruloplasmin; Q, quartile; H, high; L, low; MPO, myeloperoxi-
dase; Q, quartile.
related to increased serum Cp levels, which can affect
long-term outcomes.
The precise role that Cp plays in the pathogenesis of
cardiovascular morbidity and mortality has not been well
described, although there has been extensive literature dating
back to the 1970s describing the association between Cp and
the heart,3,15 as well as its important oxidase activities.16
Patients with MI have higher observed serum Cp levels,
which returned to normal ranges over time, suggesting its
restrictive role as an acute phase reactant.17 Nevertheless,
recent mechanistic studies show that Cp functions as an NO
oxidase in vivo, suggesting that Cp elevations may lead to
decreased NO bioavailability and endovascular dysfunction.2
Our findings are consistent with findings from prior epide-
miological data in patients without known CAD. In the
Helsinki Heart Study of dyslipidemic, middle-age men,
higher serum Cp level (but not ferritin) was associated with
graded increase in risk of cardiovascular events in a case-
control comparison.18 Another prospective cohort study of
elderly subjects also demonstrated a relationship between
serum Cp levels and subsequent development of MI, whereas
adjustment for hsCRP and leukocyte count reduced the
excess risk by 33%.5 Unlike our present study population, the
majority of patients in prior reports did not have prevalent
cardiac diseases and were not treated with cardiac or lipid-
lowering medications. It is interesting to observe that in our
patient population with contemporary cardiac care, we still
observed strong correlations between Cp and hsCRP levels
but far weaker associations with MPO and leukocyte counts.
Cytokines released from jeopardized tissues may stimulate
the liver to synthesize acute phase proteins. Cp is one of these
well-known inflammation-sensitive plasma proteins found to
have protective effects in isolated rat hearts subjected to
ischemia-reperfusion.19,20 The exact mechanisms for the car-
dioprotection are unclear but likely are due to a wide variety
of extracellular antioxidative ferroxidase and reactive oxygen
species scavenging effects,1 combined with putative
glutathione-peroxidase and NO-oxidase/S-nitrosating activi-
ties.21 Whether such potentially beneficial effects are modi-
fied by oxidative stress22,23 and progress into vasculopathic
factors that promote disease progression has been debated.24
Figure 3. Event rates for major adverse cardiac events (MACE)
stratified according to tertiles of ceruloplasmin (Cp), high-
sensitivity C-reactive protein (hsCRP) (top), and myeloperoxi-
dase (MPO, bottom).
Figure 4. Quantile-Quantile and Manhattan plots from genome-wide association study (GWAS) for serum ceruloplasmin levels. The
probability values obtained from single-nucleotide polymorphisms (SNPs) in the GWAS analyses deviate from that expected by chance,
suggesting that a subset of these signals indicate true associations (A). Serum ceruloplasmin levels in this study population (n2647)
are controlled predominantly by a locus on chromosome 3 containing the CP gene (B).
In the present study, we also used a GWAS approach to
investigate the genetic determinants of serum Cp levels, which,
to our knowledge, has not been previously reported. These
analyses revealed that common genetic determinants linked to
serum Cp levels in this white patient population are predomi-
nantly located within the CP locus. The 3 most significantly
associated SNPs are all intronic and in strong linkage disequi-
librium with each other. In addition, previous studies have
shown that plasma concentrations of Cp are regulated at the
posttranscriptional level. Specifically, a cis-regulatory element
in the 3	 untranslated region of the CP transcript called GAIT
(interferon--activated inhibitor of translation) leads to selective
translational silencing in myeloid cells.25,26
Despite the modest cis effect of the CP locus, our evalu-
ation of the lead SNP (rs13072552) did not reveal an
association with either the risk of CAD or future MACE. The
lack of such an association could be due to several factors.
For example, rs13072552 explains less than 1% of the
variation in serum Cp levels, decreasing the power for
detecting an association with cardiovascular outcomes. In
addition, serum lipid and inflammatory markers, other ge-
netic factors, and dietary/behavioral factors also contribute to
the complex pathophysiology of CAD, MI, and MACE. The
subjects used in our study were also recruited from patients
undergoing elective cardiac catheterization, which results in a
study population skewed toward individuals mostly having
documented CAD and being treated with medications to
lower their risk of future MACE. Such confounders, taken
together with the low minor allele frequency of rs13072552
and its modest effects on serum Cp levels, in combination
with the recognition that posttranscriptional processes play a
major role in Cp production, may explain, in part, the
negative association of the CP locus with CAD and MACE.
Our study is also limited by only including subjects of white
European ancestry, and additional studies in other ethnicities
and with increased power will be required to determine
whether the negative genetic findings hold true. However, it
is interesting to note that our observations with Cp are similar
to other inflammation-sensitive plasma proteins, such as
C-reactive protein, where consistent prognostic effects were
not confirmed by genetic predisposition of cardiovascular
risk in relatively large data sets.27 Thus, further studies are
also warranted to explore the molecular mechanism underly-
ing the strong association between serum Cp levels and
cardiovascular events beyond those observed with alternative
acute phase proteins (eg, hsCRP), leukocyte counts, and
traditional cardiac risk factors.
The recent discovery of a potential role for Cp as a catalytic
sink for NO consumption in vivo raises new and important
questions about the vascular function(s) and clinical utility of
this unusual copper-containing protein. The addition of Cp
testing, a readily available and affordable assay, to clinical
practice may afford synergistic prognostic value with tradi-
tional cardiac risk factors and alternative inflammation mark-
ers, such as hsCRP, MPO, and leukocyte count. In an era of
cost effectiveness, additional studies are warranted to deter-
mine whether Cp testing may provide value in prioritizing
preventive interventions among those with unrecognized
heightened cardiovascular risks.
Conclusion
In subjects undergoing elective cardiac evaluation, serum Cp
provides additive risk prediction of long-term adverse cardiac
events independent of traditional cardiac risk factors,
hsCRP, MPO, and leukocyte count. Common genetic
variants at the CP locus that are linked to serum Cp levels
are not associated with prevalent or incident risk of CAD
in this study population.










No CAD vs CAD, OR (95% CI) 1 0.99 (0.84–1.17) 1.44 (0.72–2.87) 0.74 1.01 (0.86–1.19) 0.92
No disease vs mild disease, OR (95% CI)* 1 0.92 (0.78–1.09) 1.21 (0.67–2.19) 0.61 0.94 (0.80–1.10) 0.44
No disease vs severe disease, OR (95% CI)* 1 1.04 (0.87–1.24) 0.69 (0.35–1.39) 0.93 1.02 (0.86–1.21) 0.84
CAD/MI vs CAD/MI, OR (95% CI) 1 0.97 (0.83–1.13) 1.02 (0.60–1.74) 0.77 0.97 (0.84–1.13) 0.72
Future MACE, HR (95% CI) 1 1.08 (0.91–1.28) 1.32 (0.78–2.23) 0.22 1.09 (0.93–1.29) 0.28
ORs and HRs were calculated with adjustment for age, gender, medication use (aspirin and/or statins), and Framingham risk score. OR indicates odds ratio; HR,
hazard ratio.
*Disease severity was defined as having 50% stenosis in 1 or 2 (mild) or 3 (severe) major epicardial arteries.
Table 3. Association of rs13072552 With Serum Cp Levels
Stage MAF GG GT TT P Value*
GWAS (n2647) 0.081 236 (n2234) 256 (n393) 288 (n20) 3.631013
Replication (n2050) 0.077 256 (n1774) 266 (n263) 249 (n13) 2.42102
Combined (n4697) 0.079 246 (n4008) 256 (n656) 269 (n33) 1.901011
Mean serum Cp levels are shown as a function of genotype for rs13072552. MAF indicates minor allele frequency.
*P values were obtained using log-transformed Cp values and after adjustment for age and gender.
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